Literature DB >> 25181691

A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients.

Yannick Debing1, Anett Gisa2, Kai Dallmeier1, Sven Pischke3, Birgit Bremer2, Michael Manns2, Heiner Wedemeyer2, Pothakamuri Venkata Suneetha2, Johan Neyts4.   

Abstract

We analyzed blood samples collected from 15 patients with chronic hepatitis E who were recipients of solid-organ transplants. All patients cleared the hepatitis E virus (HEV) except for 2 (nonresponders); 1 patient died. A G1634R mutation in viral polymerase was detected in the HEV RNA of the nonresponders; this mutation did not provide the virus with resistance to ribavirin in vitro. However, the mutant form of a subgenomic replicon of genotype 3 HEV replicated more efficiently in vitro than HEV without this mutation, and the same was true for infectious virus, including in competition assays. Similar results were obtained for genotype 1 HEV. The G1634R mutation therefore appears to increase the replicative capacity of HEV in the human liver and hence reduce the efficacy of ribavirin.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug Resistant; Mechanism; RNA-Dependent RNA Polymerase; Virulence

Mesh:

Substances:

Year:  2014        PMID: 25181691     DOI: 10.1053/j.gastro.2014.08.040

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  68 in total

Review 1.  [Specific infections in organ transplantation].

Authors:  M Cornberg; B Schlevogt; J Rademacher; A Schwarz; M Sandherr; G Maschmeyer
Journal:  Internist (Berl)       Date:  2016-01       Impact factor: 0.743

Review 2.  Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment.

Authors:  Nassim Kamar; Sven Pischke
Journal:  Cold Spring Harb Perspect Med       Date:  2019-07-01       Impact factor: 6.915

3.  Antiviral Candidates for Treating Hepatitis E Virus Infection.

Authors:  Natalie E Netzler; Daniel Enosi Tuipulotu; Subhash G Vasudevan; Jason M Mackenzie; Peter A White
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

4.  Potent Inhibition of Hepatitis E Virus Release by a Cyclic Peptide Inhibitor of the Interaction between Viral Open Reading Frame 3 Protein and Host Tumor Susceptibility Gene 101.

Authors:  Saumya Anang; Nidhi Kaushik; Smita Hingane; Anita Kumari; Jyoti Gupta; Shailendra Asthana; Baibaswata Nayak; C T Ranjith-Kumar; Milan Surjit
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

5.  The IMPDH inhibitors, ribavirin and mycophenolic acid, inhibit peste des petits ruminants virus infection.

Authors:  Qiu-Yan Chang; Fu-Cheng Guo; Xue-Rui Li; Jian-Hua Zhou; Xuepeng Cai; Qiuwei Pan; Xiao-Xia Ma
Journal:  Vet Res Commun       Date:  2018-08-09       Impact factor: 2.459

6.  Pan-Genotype Hepatitis E Virus Replication in Stem Cell-Derived Hepatocellular Systems.

Authors:  Xianfang Wu; Viet Loan Dao Thi; Peng Liu; Constantin N Takacs; Kuanhui Xiang; Linda Andrus; Jérôme Gouttenoire; Darius Moradpour; Charles M Rice
Journal:  Gastroenterology       Date:  2017-12-24       Impact factor: 22.682

Review 7.  Hepatitis E virus: advances and challenges.

Authors:  Ila Nimgaonkar; Qiang Ding; Robert E Schwartz; Alexander Ploss
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-11-22       Impact factor: 46.802

8.  Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target.

Authors:  Changbo Qu; Shaoshi Zhang; Wenshi Wang; Meng Li; Yijin Wang; Marieke van der Heijde-Mulder; Ehsan Shokrollahi; Mohamad S Hakim; Nicolaas J H Raat; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  FASEB J       Date:  2018-08-02       Impact factor: 5.191

9.  Transmission of a Novel Genotype of Hepatitis E Virus from Bactrian Camels to Cynomolgus Macaques.

Authors:  Lin Wang; Jade L L Teng; Susanna K P Lau; Siddharth Sridhar; Hongwei Fu; Wanyun Gong; Manyu Li; Qieshi Xu; Yunye He; Hui Zhuang; Patrick C Y Woo; Ling Wang
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

10.  Viral Macro Domains Reverse Protein ADP-Ribosylation.

Authors:  Changqing Li; Yannick Debing; Gytis Jankevicius; Johan Neyts; Ivan Ahel; Bruno Coutard; Bruno Canard
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.